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In resource-limited areas, isolation of the sick from the population at large has been the cornerstone 
of control of Ebola virus disease (EVD) since the vi-
rus was discovered in 1976.1 Although this strategy 
by itself may be effective in con-
trolling small outbreaks in re-
mote settings, it has offered little 
hope to infected people and their 
families in the absence of medi-
cal care. In the current West Af-
rican outbreak, infection control 
and clinical management efforts 
are necessarily being implement-
ed on a larger scale than in any 
previous outbreak, and it is 
therefore appropriate to reassess 
traditional efforts at disease 
management. Having cared for 
more than 700 patients with EVD 
between August 23 and October 
4, 2014, in the largest Ebola treat-
ment unit in Monrovia, Liberia 
(see diagrams), we believe that 
our cumulative clinical observa-
tions support a rational approach 
to EVD management in resource-
limited settings.
Early symptoms of EVD in-
clude high fever (temperature of 
up to 40°C), malaise, fatigue, and 
body aches (see table).2,3 The fever 
persists, and by day 3 to 5 of ill-
ness, gastrointestinal symptoms 
typically begin, with epigastric 
pain, nausea, vomiting, and diar-
rhea. Patients routinely presented 
to our facility after 2 or 3 days of 
severe vomiting or diarrhea, dur-
ing which they posed a substan-
tial risk to their communities and 
had a high probability of testing 
positive for Ebola virus in blood by 
polymerase chain reaction (PCR). 
Although some patients tested 
positive on PCR within 24 hours 
after symptom onset, we found 
that a negative test result could 
not be relied on to rule out dis-
ease until 72 hours after symp-
toms began. Of the patients who 
tested positive for Ebola, none 
that we were aware of had con-
tracted disease from an infected 
contact during the early febrile 
phase of illness. No ancillary test-
ing was available in our facility.
We observed that recurrent 
episodes of emesis resulted in an 
inability to tolerate oral intake. 
Large volumes of watery diarrhea 
estimated at 5 or more liters per 
day (a manifestation not unlike 
that of cholera) presented sud-
denly, persisted for up to 7 days 
or (rarely) longer, and gradually 
tapered off. Associated signs and 
symptoms included asthenia, 
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headache, conjunctival injection, 
chest pain, abdominal pain, ar-
thralgias, myalgias, and hiccups. 
Respiratory symptoms, such as 
cough, were rare. Commonly ob-
served neurologic symptoms in-
cluded delirium, both hypoactive 
and hyperactive, manifested by 
confusion, slowed cognition, or 
agitation, and less frequently, 
seizures. In the absence of ade-
quate f luid and electrolyte re-
placement, severe lethargy and 
prostration developed.
In approximately 60% of the 
patients we cared for, the devel-
opment of shock was manifest-
ed by diminished level of con-
sciousness or coma, rapid thready 
pulses, oliguria or anuria, and 
tachypnea. The distal extremities 
were cold despite high ambient 
temperature, and peripheral va-
soconstriction was apparent. In 
aggregate, these clinical findings 
suggested metabolic acidosis due 
to severe hypovolemic shock. Evi-
dence of hyperdynamic or dis-
tributive shock was infrequently 
observed and if present was a 
late finding. Clinically signifi-
cant hemorrhage from the upper 
or lower gastrointestinal tract or 
both occurred in less than 5% of 
patients before death. Sudden 
death occurred in a small frac-
tion of patients who were in the 
recovery phase of their illness, 
possibly as the result of fatal ar-
rhythmias. Most deaths occurred 
between days 7 and 12 of illness.
Symptoms began to improve 
in approximately 40% of patients 
around day 10 of illness. We ob-
served the development of oral 
ulcers and thrush around this 
time, associated with throat pain 
and dysphagia. Nearly all pa-
tients who survived to day 13 ul-
timately lived. Our discharge cri-
teria included 3 days without 
gastrointestinal symptoms and a 
negative PCR test for Ebola virus 
in blood. We noted that some pa-
tients with initial evidence of 
clinical improvement developed 
neck rigidity and diminished lev-
els of consciousness. These symp-
toms were associated with a slight 
increase in late mortality. The 
role of central nervous system in-
volvement by EVD, secondary in-
fection, or aseptic processes could 
not be assessed.
Particularly vulnerable patient 
populations included children 
less than 5 years of age, the el-
derly, and pregnant women. Of 
the four women who presented 
with late second- or third-trimes-
ter pregnancies, three died shortly 
after miscarrying, and none suc-
cessfully carried a fetus to term. 
Four Liberian staff members be-
came infected with Ebola virus, 
and three of them died. Accord-
ing to individual investigations, 
these infections were not attribut-
able to any known breaches in 
infection-control procedures in 
the Ebola treatment unit; instead 
they are thought to be possibly 
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related to transmission in the 
community where the outbreak 
was active.
Health care workers in West 
Africa remain overwhelmed and 
challenged by the scarcity of re-
sources that would be available 
in developed countries for improv-
ing the care of patients with EVD.4 
When patients arrived at our fa-
cility, they were moderately to 
severely ill, and each physician 
was responsible for the care of 
30 to 50 patients. Direct patient 
contact in the Ebola treatment 
center was typically limited to in-
tervals of 45 to 60 minutes two 
to three times a day, owing to 
substantial heat exposure and 
fluid losses that providers expe-
rienced while wearing full per-
sonal protective equipment (PPE). 
Under these conditions, physicians 
had 1 to 2 minutes per patient to 
evaluate needs and establish a 
care plan.
Rapid clinical assessment re-
quired triage of patients into one 
of three categories: those who 
were clinically hypovolemic, not 
in shock, and able to provide 
self-care; those who were hypo-
volemic, not in shock, but unable 
to provide self-care; and those in 
shock with evidence of organ 
failure whose outcome would not 
be altered by any available medi-
cal intervention. The majority of 
patients we cared for were in the 
first category. We believe that 
this group had the highest likeli-
hood of having a response to our 
limited available interventions.
We observed that patients who 
were hypovolemic, not in shock, 
and able to care for themselves 
had potential for recovery with 
oral antiemetics, antidiarrheal 
therapy, and adequate rehydra-
tion with oral electrolyte solu-
tions. Given the massive fluid 
losses observed with EVD, oral 
antiemetics and antidiarrheal 
therapy appear to be important 
early interventions that may limit 
life-threatening dehydration and 
shock. In our experience, these 
regimens were successful at 
controlling symptoms, facilitated 
oral intake, reduced gastrointes-
tinal fluid losses, and helped to 
reduce environmental contamina-
tion by body fluids. Health care 
workers with limited time in PPE 
were then able to direct their ef-
forts toward encouraging and fa-
cilitating oral intake.
It was our impression that the 
cohort of patients who were hypo-
volemic and not in shock but un-
able to provide self-care would 
benefit the most from short-term 
intravenous fluid therapy and elec-
trolyte replacement. Establish-
ing intravenous access, delivering 
an adequate volume of fluid, and 
ensuring safe management of 
needles and devices required inten-
sive individual-level patient care. 
Routine use of intravenous fluid 
therapy in our facility was prohib-
ited by massive caseloads, limited 
number of health care workers, 
and limited time in PPE.
The central purpose of Ebola 
treatment units has historically 
been to isolate infected persons 
early in the course of disease — 
often soon after fever onset — in 
order to break the chain of dis-
ease transmission in the commu-
nity. However, all efforts must be 
made to optimize the level of med-
ical care provided within these 
facilities. Resistance by infected 
people to voluntary admission will 
persist unless the treatment fa-
cilities are seen as a place to go 
for treatment and recovery and not 
as a place to die isolated from 
loved ones and the community. 
Our observations support aggres-
sive use of antiemetics, antidiar-
rheal medications, and rehydra-
tion solution to reduce massive 
gastrointestinal losses and the 
consequences of hypovolemic 
shock. Selective use of intrave-
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Clinical Features of Ebola Virus Disease.
Phase of Illness
Time since 
Symptom Onset Clinical Features
Early febrile 0–3 days Fever, malaise, fatigue, body aches
Gastrointestinal 3–10 days Primary: epigastric pain, nausea, vomiting, diarrhea
Associated: persistent fever, asthenia, headache, conjunctival injection, chest pain, 
 abdominal pain, arthralgias, myalgias, hiccups, delirium
Shock or recovery 7–12 days Shock: diminished consciousness or coma, rapid thready pulse, oliguria, anuria, tachypnea
Recovery: resolution of gastrointestinal symptoms, increased oral intake, increased energy
Late complications ≥10 days Gastrointestinal hemorrhage, secondary infections, meningoencephalitis, persistent 
neurocognitive abnormalities*
* Secondary infections are presumptive diagnoses based on clinical features of distributive shock, oral or esophageal candidiasis, 
and oral ulcers; meningoencephalitis is a presumptive diagnosis based on clinical features of unconsciousness and stiff neck.
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nous fluid therapy in the popula-
tion that is most likely to benefit 
is a rational approach under the 
current circumstances. When pos-
sible, broader use of intravenous 
f luid therapy and electrolyte re-
placement, guided by point- 
of-service laboratory testing, is 
likely to significantly improve 
outcomes.
Disclosure forms provided by the authors 
are available with the full text of this article 
at NEJM.org.
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